Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

Sumitomo Dainippon Pharma to Expand Regenerative and Cellular Medicine CDMO Operations

Filed Under: Pharma Tagged With: , , , ,

Sumitomo Dainippon Pharma Co. Ltd. (TYO:4506) and Sumitomo Chemical Co. Ltd. (TYO:4005) plan to expand their CDMO facilities for regenerative…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

Sumitomo Chemical President Keiichi Iwata Lays out Plan to Get Core Operating Income to 280B Yen
Sumitomo Chemical President Keiichi Iwata Lays out Plan to…
Teijin Expands Health Care Operations for Bone and Joint Diseases
Teijin Expands Health Care Operations for Bone and Joint…
Mitsui Chemicals to Re-Enter Nucleic Acid Drug CDMO Market
Mitsui Chemicals to Re-Enter Nucleic Acid Drug CDMO Market
Mitsubishi Chemical to Produce Regenerative Medicine Materials From Plants
Mitsubishi Chemical to Produce Regenerative Medicine…
Chemical and Material Companies Look to Take Pharmaceutical Operations to the Next Stage
Chemical and Material Companies Look to Take Pharmaceutical…
Sumitomo Chemical Eyes Core Operating Income of 280B Yen in New Medium-Term Management Plan
Sumitomo Chemical Eyes Core Operating Income of 280B Yen in…